UNION CITY, Calif.– Celltheon today announced the commercial launch of its CHO-K1 based OmniCHO™ Transient Expression Kit, a breakthrough technology poised to transform preclinical drug development.
The OmniCHO™ kit offers unparalleled productivity, producing average antibody titers of 2 grams per liter of culture—a task that typically requires 10-20 liters with conventional expression kits. This exceptional performance translates to a 6 to 30-fold decrease in costs per milligram of protein compared to competing systems. The kit’s versatility is demonstrated by its ability to express both easy and difficult-to-express proteins, including challenging fusion proteins, antigens, and bispecifics, making it a valuable tool for a wide range of research applications.
OmniCHO™’s scalability is another key feature, maintaining high productivity across various scales, from 96-well deep well plates to 50-liter bioreactors. Importantly, the system achieves yields exceeding 1 g/L in 5 days, significantly accelerating research timelines in preclinical drug development.
“OmniCHO™ represents a quantum leap in transient protein expression,” said Nikhil Goel, CTO of Celltheon. “We are not just improving the process; we are fundamentally changing the economics of preclinical research.”
Complementing the kit, Celltheon offers comprehensive end-to-end services utilizing OmniCHO™ technology, including gene synthesis, production, purification, and advanced analytics. This integrated approach can deliver hundreds of grams of high-quality protein in just four weeks, further streamlining the drug development process.
